Pharma Exclusives Pressreleases

Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research

Tuesday, June 03, 2025

Thermo Fisher Scientific Inc the world leader in serving science today announced the launch of the Thermo Scientific Orbitrap Astral Zoom mass spectrometer MS and the Thermo Scientific Orbitrap Excedion

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Tuesday, June 03, 2025

Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration treatment options

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

Saturday, May 31, 2025

Moderna Inc today announced that the US Food and Drug Administration FDA has approved mNEXSPIKE mRNA a new vaccine against COVID for use in all adults and older as well as individuals

Merck Reports Positive Phase 2 Results for Zilovertamab Vedotin Combined with Standard Treatment in Relapsed/Refractory DLBCL Patients

Friday, May 30, 2025

Merck known as MSD outside of the United States and Canada today announced results from the dose confirmation portion of the Phase waveLINE study evaluating zilovertamab vedotin in combination

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Friday, May 30, 2025

Pfizer Inctoday announced statistically significant and clinically meaningful survival results from the Phase BREAKWATER trial evaluating BRAFTOVI encorafenib in combination with cetuximab marketed as ERBITUX and mFOLFOX fluorouracil leucovorin and...

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

Thursday, May 29, 2025

Eton Pharmaceuticals Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases today announced the US Food and Drug Administration FDA approval of a New Drug Application

Patritumab Deruxtecan Biologics License Application for Patients With Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

Thursday, May 29, 2025

The Biologics License Application BLA seeking accelerated approval in the US for Daiichi Sankyo TSE and Mercks NYSE MRK known as MSD outside of the United States and Canada patritumab deruxtecan HERDXd based on the HERTHENALung Phase trial for the...

Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs

Thursday, May 29, 2025

Thermo Fisher Scientific Inc the world leader in serving science today launched the spectralenabled Invitrogen Attune Xenith Flow Cytometer allowing immunology and immunooncology researchers to automate and streamline workflows

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Wednesday, May 28, 2025

Eli Lilly and Company and SiteOne Therapeutics Inc a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders today announced a definitive agreement for Lilly t...

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Wednesday, May 28, 2025

Teva Pharmaceutical Industries Ltdtoday announced that the US Food and Drug Administration FDA granted Fast Track designation for investigational TEV an antiIL antibody for the treatment of people with celiac disease